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Preface 
 
 
This report continues two important research programmes at the AERU. The first programme 
focuses on the social and economic impacts of new technologies, particularly as they affect 
food and agriculture. Technologies assessed in prior AERU research include genetic 
modification, biopharming, various other biotechnologies, and nanotechnology. The second 
research programme uses a model of international trade in agricultural commodities to 
evaluate potential economic impacts on New Zealand and other countries. These impacts may 
result from technological changes and/or policy initiatives. The research reported here 
quantifies the potential impacts on New Zealand agriculture of adopting a new technology, 
using the trade model. The results are relevant from both policy and agricultural perspectives. 
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Executive Summary 
 
 
Biopharming is an agricultural technology on the cusp of commercialisation. The technology 
uses genetically modified crop plants and animals to produce pharmaceuticals. Biopharm 
crops are now grown in the United States and Europe, and biopharm animals are being raised 
in New Zealand and elsewhere. The Agribusiness and Economics Research Unit (AERU) 
conducted research on the industry in 2006 and 2007 (Kaye-Blake, Saunders, & Ferguson, 
2007), finding that ‘the necessary information to develop a robust economic analysis of these 
products is lacking. Much of the information on the relevant dimensions is simply unknown.’ 
 
This report builds on the prior AERU study. First, it presents an update on the biopharming 
industry and the economics literature on it. Secondly, it presents economic modelling to 
estimate the potential impacts of biopharming in New Zealand. This analysis uses the Lincoln 
Trade and Environment Model (LTEM) to simulate different market impacts from 
biopharming and estimate the net economic impacts. Finally, the ramifications of these 
estimates for biopharming in New Zealand are discussed. 
 
The literature on biopharming has not developed appreciably in the last year or two. There 
are still a number of unknowns, and its profitability and potential impacts on the wider 
agricultural sector depend on the pharmaceutical, crop, and region being studied. Consumer 
reactions appear to be a significant factor. Consumer perceptions of biopharming and the 
food system are presented in the literature in essentially three ways. One model of 
perceptions is ecological: it considers the biopharm organism in an agro-ecological 
environment. A second model is genetic, and focuses on the potential for modified genes to 
escape the biopharm crop or animal and enter the genome of other organisms. The third 
model considers how food is produced and the potential for mixing biopharm material with 
food crops and ingredients in the food industry. 
 
A model of international trade in agricultural commodities – the LTEM – was used to analyse 
the impact of changes in agricultural markets due to the introduction of biopharming into the 
dairy sector in New Zealand. The results provided information about the relative sizes of 
potential economic impacts given different future changes in the markets. Biopharming could 
have either positive, neutral, or negative impacts on the demand for New Zealand dairy 
products. In addition, it may be pursued without any impact on the cost structure of the wider 
dairy sector, but it could impose segregation or similar costs on non-biopharm producers.  
 
A set of scenarios was developed based on these possibilities and modelled. The scenarios 
included some with no production impact and others with five per cent and 10 per cent 
increases in production costs. Consumer reactions were modelled with scenarios that included 
either no change in demand; a 10 per cent increase in demand; or a 10, 20, or 50 per cent 
reduction in demand. The production and consumption changes were combined into a total of 
15 scenarios, including the base scenario. 
 
The modelling results indicated that biopharming could affect agriculture either positively or 
negatively. The main factor in determine the size and direction of the effect was the change in 
demand. If demand for dairy products increases (because the products are of higher value and 
farmers are paid a premium), then the net impact is likely to be positive. If consumers 
become wary of New Zealand dairy products, then the result is likely to be negative. Of less 
importance is the imposition of greater costs on the sector for segregation, which created 
reductions of less than two per cent in agricultural revenues. 
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The results from the trade modelling provide a baseline for a cost-benefit analysis 
biopharming. If biopharming results in higher agricultural revenues, then the total economic 
impact is likely to be positive. If, on the other hand, biopharming causes losses in the 
agricultural sector, these losses would need to be offset by earnings from the biotechnology 
or pharmaceutical industries. The modelling results put these potentially lost revenues at 
between $133 and $3,352 million annually in current dollars. 
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Chapter 1 
Introduction 
 
 
Biopharming is one of two current technological trajectories in agricultural that could have 
significant impacts on farming systems, the other being biofuel production. Biopharming, in 
which pharmaceutical compounds are produced in plant and animal tissue in agricultural 
systems, is being pursued by several different companies using a variety of production 
systems. Biopharm crops are already being grown in the open in the United States and 
Europe, and biopharm animals are already being raised in New Zealand and elsewhere. 
 
Companies and scientists developing this technology are optimistic about its potential, both 
for improving human health and for producing economic returns. As a distinct, developing 
technology, however, its economics have been little studied in the academic literature. Only a 
handful of economic studies exploring the complex impacts of biopharming on the 
pharmaceutical and agricultural sectors appears in the peer-reviewed literature (e.g., DiMasi, 
2007; Elbehri, 2005; Kostandini, Mills, & Norton, 2006), and a few more studies are also 
available (e.g., GianCarlo, 2006; Wisner, 2005). The Agribusiness and Economics Research 
Unit (AERU) conducted an extensive literature review and survey of the industry in 2006 and 
2007, and amassed a list of extant examples of biopharmed products (Kaye-Blake et al., 
2007). The results of that study bear citing here: 
 
The main result from this examination is that the necessary information to 
develop a robust economic analysis of these products is lacking. Much of the 
information on the relevant dimensions is simply unknown. A second result 
from this work is that the potential value of these products varies 
tremendously, depending on the overall size of the potential market, control of 
technology or proprietary information, and other factors. A third concern is 
adverse reactions in overseas markets. The future impact of consumer 
concerns is uncertain and contested. (p. 37) 
 
The present research builds on the prior AERU study. First, it presents an update on the 
biopharming industry and the economics literature on it. Secondly, it presents economic 
modelling to estimate the potential impacts of biopharming in New Zealand. This analysis 
used the Lincoln Trade and Environment Model to simulate different market impacts from 
biopharming and estimated the net economic impacts. Finally, the ramifications of these 
estimates for biopharming in New Zealand are discussed. 
 2
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Chapter 2 
Update on Biopharming 
 
 
The AERU published an earlier report (Kaye-Blake et al., 2007) that examined the state of 
the biopharming industry, the products and companies involved, and economic studies that 
had been conducted. That report also discussed the nature of New Zealand agriculture and 
established a framework for considering the potential impacts of biopharming on the country. 
For a full discussion of the industry and relevant economic issues, the reader is directed to 
that report. 
 
The present chapter summarises and updates that research. The next section briefly 
summarises the earlier report to provide context. There then follows an update on the 
economic research into biopharming. The final section provides empirical motivation for the 
modelling scenarios analysed in this research. 
 
2.1 Summary of prior study 
Biopharming is still in a research stage; it is not a developed industry with commercial 
products and commercial revenue. Available valuations of products and companies or 
estimates of economic benefits are not based on market transaction for final products. 
Instead, those valuations are based on projections of the future market value to be realised 
from present research.  
 
Economic information on the biopharming industry is difficult to find, and comes largely 
from two sources: the non-academic press and economic information contained in non-
economic publications. Biopharming is one area of a larger industry focused on producing 
biological compounds of pharmaceutical interest. Biopharming uses genetically modified 
plants or livestock to produce these compounds, which are then extracted and purified. One 
such product seemed to be commercially available. These same compounds may also be 
produced using other non-biopharming technology, such as cell culture, and those 
compounds are in total worth between US$40 and US$60 billion per year. 
 
One way to assess biopharming is to consider how it differs from other possible ways of 
producing similar compounds. Prior research has found that biopharming is an improvement 
on prior technologies in some ways, but also may not perform as well in others. Some of 
these differences are physical, such as differences in protein yield and structure. Aspects that 
could significantly affect the economics of biopharming can be divided into supply and 
demand impacts. On the supply side, interest in biopharming appears to be driven largely by 
production costs. Costs comparisons ran the gamut, from biopharmed compounds costing 
one-fiftieth the cost of current methods (Kusnadi, Nikolov, & Howard, 1997) to offering no 
cost savings at all (Wisner, 2005). On the demand side, there is a public perception that 
biopharming entails greater risks than current production methods. 
 
A model was developed to estimate the economic potential of biopharming. The model 
treated each compound as a bundle of characteristics, and related the cost of producing a 
compound to the costs of the discrete characteristics. More precisely, the difference in cost 
between a conventional biologic and a biopharmed biologic is a function of the value of the 
changes in all the characteristics. This model was applied to two products: recombinant 
human lactoferrin (rhLF) and low-GI (glycaemic index) potatoes. For both products, there 
was insufficient information to apply the model fully. For the rhLF, it appeared difficult to 
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earn more than an economically normal profit. There seemed to be several close substitute 
products and competing technologies, so little opportunity to create a dominant position in 
the market and earn oligopoly or monopoly profits. Low-GI potatoes, on the other hand, 
could have clear consumer appeal in the functional foods market, which is a multibillion 
dollar and expanding market segment (Sloan, 2006). As a functional food, it would have 
lower regulatory hurdles than a biopharmaceutical. Furthermore, potatoes are a commonly 
consumed food, and the total market is again a multibillion dollar market. 
 
2.2 Research update 
Mewett et al. (2007) reviewed the current state of development of biopharming. They found 
that ‘only a small number of plant-made research and analytical-grade proteins hav[e] 
reached the commercialisation stage of the product development pipeline’ (p. 17). They 
specified six products – three proteins, two enzymes, and one gene – produced through plant 
biopharming that have reached commercial production in the US. Of the four companies 
named as involved in commercialising these compounds, two are in voluntary receivership. 
As a result, two of the six products may no longer be available.  Examining the Australian 
situation, they found a number of plant-made pharmaceuticals under development but did not 
describe any in commercial production. 
 
One of the ongoing issues in biopharming is the organism that is used as the platform or 
bioreactor. Many different species of plants and animals have been used to produce 
pharmaceutical compounds, at least in research situations. However, one species has been 
used overwhelmingly for field trials of plants producing pharmaceutical or industrial proteins 
– maize (Marvier, 2007). Ramessar et al. (2008) examined the case for using maize, and 
concluded that several characteristics made it the best choice for biopharming. Amongst other 
traits, the seed is easy to handle and high in protein (so it concentrates the pharmaceutical 
protein), the plant grows well because of its C4 pathway (most grains use a C3 pathway 
(Pollan, 2006)), maize is widely consumed and not allergenic, and research has proven it 
effective for delivering oral vaccines to pigs (Ramessar et al., 2008). On the other hand, a 
number of researchers have expressed concern with using food crops as bioreactors (e.g., 
Marvier, 2007; Spok, 2006). They argue that using non-food crops would reduce the risk that 
biopharm material might enter the food supply. 
 
The focus on maize could be a function of the geographic distribution of biopharming 
research: maize was by far the most commonly used platform in the US, but safflower and 
tobacco were the most common crops in Canadian field trials, and maize was second to 
tobacco in field trials in Europe (Bauer, 2006). Mewett at al. (2007) found that Australian 
research to commercialise plant-made pharmaceuticals had looked at tobacco, sugarcane, and 
tomatoes as possible bioreactors. New Zealand research has used animals, such as dairy 
cattle, as bioreactors (Laible & Wells, 2007). In this vein, animal cloning has been advocated 
as a way to develop high-value herds of genetically consistent animals (Laible & Wells, 
2007). 
 
The economic viability of biopharming generally is still uncertain. Researchers assert that 
‘[p]lants offer …an inexpensive way to produce pharmaceutical proteins’ (Ramessar et al., 
2008, p. 410), for example, monoclonal antibodies to treat viral diseases (Marasco & Sui, 
2007, p. 1432)1. There are differences between existing commercial methods for producing 
 
1 The assertions of  Ramessar et al. (2008) and Marasco & Sui (2007) follow many others in describing the 
economic efficiency of biopharming (see Kaye-Blake et al., 2007). However, Spok (2006) suggested, ‘Until 
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pharmaceutical proteins and biopharming methods (Ramessar et al., 2008), but the economic 
impacts of those differences have yet to be fully assessed. For the specific case of vaccines 
delivered through biopharm food, the commercial viability has also not been established 
(Mewett et al., 2007). For example, growing sufficient quantities of biopharmaceutical crops 
may be relatively inexpensive, but processing the raw agricultural product to recover the 
pharmaceutical would account for 80 per cent or more of the costs of production (Ramessar 
et al., 2008). Current commercial methods of producing biologics face similar issues: 
growing yeast and bacteria is relatively cheap, but processing according to Good 
Manufacturing Practice is expensive (Mewett et al., 2007). An additional consideration is that 
some applications of pharmaceutical proteins, regardless of how they are produced, have 
encountered challenges in the clinic and in the marketplace (Marasco & Sui, 2007). 
 
The scale of required biopharming production will likely be small. One estimate found that 
15,000 acres of safflower would meet worldwide insulin demand in 2012 (Ramessar et al., 
2008). Another example considered the production of the human protein vitronectin in GM 
tobacco: global needs could be met with the production from one glasshouse (Mewett et al., 
2007). If animals are used as bioreactors, again the scale is likely to be small, at least initially 
(Laible & Wells, 2007). This small scale is not surprising, given the overall size of the market 
for therapeutic proteins, of which biopharming is only one part. Murphy (2007) cited 2004 
research valuing the entire market for such proteins at $20 billion (presumably US dollars), 
with a growth rate of 15 per cent. The 2010 value for the market would thus be approaching 
$50 billion, although Murphy (2007) cited additional research forecasting the 2010 market 
value at $140 billion. 
 
The crops used to produce biopharmaceuticals are created using genetic modification and are 
therefore genetically modified organisms (GMOs). One of the issues surrounding GMOs in 
agriculture is co-existence, the possibility and difficulties of growing crops for different uses 
and markets (Fontes, 2007; Miranowski et al., 1999). Earlier research focused on the 
possibility that GMOs could ‘contaminate’ organic agriculture (which does not permit the use 
of GMOs), and concluded that strict segregation was impossible (Fontes, 2007). Instead, 
thresholds of permissible presence of GM material were advocated (Spok, 2006). By contrast, 
the development of biopharming appears to have led to calls for stricter segregation (Spok, 
2006). The potential health impacts should pharmaceutical crops enter the food supply is one 
clear concern (Fontes, 2007; Mewett et al., 2007). In addition, concern about protecting the 
purity of high-value biopharm crops may mean that segregation will also focus on keeping 
the food crops out of biopharm production (Mewett et al., 2007; Spok, 2006). Researchers 
believe that biopharm crops can be segregated and contained (Mewett et al., 2007; Murphy, 
2007), and point to the current success with segregating food-grade and industrial rapeseed, 
suggesting that this experience can be transferred to biopharming (Ramessar et al., 2008). 
The issue of co-existence is particularly acute in ‘centres of origin’, the geographical areas 
where particular crop species originate, which still contain genetic diversity for the species 
and its close relatives (Fontes, 2007). 
 
Where researchers advocate solutions to the issues facing biopharming, they often suggest 
that greater international cooperation and harmonisation of regulations would be helpful. For 
example, on the issue of co-existence, Fontes (2007) states, ‘It is important that all 
agricultural sectors – GM, non-GM and organic alike – embrace the concept of coexistence 
and work together to accommodate each other’ (p. 4). Lack of harmonisation would increase 
the complexity of international trade in food and feed, as exporters worked to meet different 
standards in different countries (Spok, 2006). 
 
recently, potential savings in production costs were strongly emphasized, with industry, in the mean time, 
becoming less optimistic’ (p. 75). Spok focused instead on other potential benefits. 
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The framework for assessing the potentials and risks of biopharming has also received 
attention. Three main approaches have been discussed (Marvier, 2007). The precautionary 
approach focuses on the risk, so that biopharming would not be allowed to proceed until the 
producer demonstrated the safety of the production method. A risk-assessment framework 
assesses both the probability of a risk and the magnitude of its potential impact. It attempts to 
identify the specific impacts and the pathways that could lead to those impacts, and then 
quantify the probabilities. It also takes the seriousness of the risk into account. Finally, a cost-
benefit analysis assesses the potential rewards from biopharming and evaluates them against 
the costs. Such an analysis could include equity considerations, and might also examine the 
relative costs and benefits of alternative methods of producing the same health outcomes. 
 
2.3 Potential impacts 
Biopharming relies in part on natural production systems operating in the open. It is therefore 
competing for some of the same resources as agriculture and tourism. The agricultural sector 
depends on the biological resources to produce not only food and fibre for the domestic 
population but also for a large percentage of the country’s exports. Together, agriculture, 
forestry, and their associated sectors contributed 18 per cent of the country’s GDP in 2002/03 
(Ministry of Agriculture and Forestry, 2005). In addition, agricultural and silviculture exports 
accounted for over 60 per cent of merchandise exports (Ministry of Agriculture and Forestry, 
2005). International tourism also depends on the country’s natural resources, its biology and 
landscape, benefiting from New Zealand’s image as a clean and green destination. Tourism 
also adds significantly to the country’s export earnings. The Tourism Satellite Account 
(Statistics New Zealand, 2006), which calculates the contribution of tourism to the New 
Zealand economy, shows a total tourism expenditure of $17.5 billion for the year ending 
March 2005, contributing nine per cent of gross domestic product. Of this amount, 46 per 
cent was contributed by international tourists, so that tourism is New Zealand’s largest export 
earner. 
The present research focuses in particular on the interactions between biopharming and the 
rest of agriculture. The potential impacts can be divided into those that affect the supply or 
production side of the market, and those that affect demand or consumption. The supply side 
impacts have the potential to affect both pharmaceutical production and the agricultural 
production of food and fibre. For pharmaceutical production, the cost savings may allow 
pharmaceutical companies to supply more product, charge lower prices, or do both. 
Biopharming may also allow pharmaceutical companies to produce new compounds or 
improve the safety of biologic compounds. However, the main thrust of biopharming in the 
present and near future is producing currently available compounds at lower cost (Kaye-
Blake et al., 2007). The supply side impacts on agriculture are less clear. Biopharming will 
take resources from other agriculture – land, water, labour, capital, etc. This direct effect is 
likely to be small because only a small fraction of total arable acreage will be required. 
Biopharm crops also represent a potential high-value crop for farmers. The value of the crops 
will depend on several factors, including the market value of the biologic compound, its 
concentration in the crop, and the costs of extraction. Farmers are likely to be paid a premium 
to grow biopharm crops, increasing the returns to agriculture. The ultimate size of these 
premiums will depend on the competition for resources – including farmers’ skill – and 
relative market power. Given the imperfectly competitive structure of the pharmaceutical 
industry, market power is more likely to favour the pharmaceutical firms than individual 
farmers. In addition, while premiums may improve the economic performance of specific 
farms or even specific regions, the size of biopharming relative to the rest of agriculture 
would dilute the contribution of these premiums to agriculture as a whole. 
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The demand effects of biopharming are also complex and uncertain. On the demand side, it is 
important to consider the effect that a biopharm crop could have on its conventional 
counterpart, especially if they are grown in the same region. California farmers, for example, 
opposed an application by Ventria Bioscience to grow biopharm rice modified with synthetic 
human genes (Marvier, 2007). They were concerned that any amount of contamination of 
food rice would pose problems for their customers. Nor are the farmers’ concerns unfounded: 
contamination of the US rice crop with an unapproved GM variety cost the rice growers 
around $150 million in lost exports to the EU (Marvier, 2007). 
 
A biopharm crop is a hybrid product, with both agricultural and pharmaceutical aspects. 
There will be demand-side effects for both aspects. For the pharmaceutical compound, the 
extent to which it is better than existing products will affect demand. The product may have 
close substitutes, such as similar biologic compounds produced with a different production 
technique. The economic benefits of biopharming would thus need to be assessed on a case-
by-case basis, as they depend on the specific compound. For the agricultural aspect of a crop, 
the economic impact will depend in large part on consumers’ reactions. If consumers 
perceive that the potential for biopharming to ‘contaminate’ food crops is high, then the 
biopharm crop may have significant negative impacts on the wider agricultural sector. 
Furthermore, if adventitious presence does arise, such that the biopharm crop does appear in 
the food supply, the demand impacts are likely to depend on consumer perceptions, 
regulatory behaviour, and private sector management of the incident (Slovic, 2000). 
 
It seems logical to look to the literature on GM food to find indications of how consumers 
might react to GM biopharm crops. Much of the literature on GMOs has considered 
consumer reactions, drivers of consumer attitudes, heterogeneity across and within countries, 
information impacts, economic impacts of demand shifts, and whether consumers are right in 
their assessments. What appears to have received less attention is how consumers assess the 
potential for ‘contamination’ to spread from a GM crop to a non-GM one. The way that 
consumers understand or make sense of contamination may be important, because it may 
affect how consumers view potential biopharm contamination and the likelihood of it 
happening. 
 
In the literature on GM food and biopharming, three different models appear to underlie how 
interactions between GMOs and the food system are presented. They are not mutually 
exclusive, but different models are emphasised in different discussions of the impacts of 
GMOs. One model is ecological: it considers the GMO as an organism in an agro-ecological 
environment. This model is shown in Figure 1. The GMO can contaminate the farm’s own 
ecology as well as the surrounding environment, and the contamination is the result of 
changing or disrupting natural processes. For example, participants in focus groups in Canada 
were concerned about the possibility of biopharm products entering the food chain through 
pollen movements or because of wind, insects, or animals (Einsiedel & Medlock, 2005). The 
extent of the impact can be described by an oval that takes in some part of the farm and, 
potentially, some surrounding environment. 
 
Figure 1: Ecological model of GMO impacts 
 
 
Farm 
Environment 
            Extent of 
            contamination GMO 
 
 
 
 
 
 
 
 
 
 
 
 
A second mental model is genetic, and focuses on the potential for modified genes to escape 
the GMO and enter the genome of other organisms. As shown in Figure 2, there are two 
components to this model. The first component is based on systematic biology, and considers 
the possibility for transmission of modified genes through sexual reproduction (Fontes, 2007; 
Mewett et al., 2007). A GMO could cross-breed with a closely related species and the 
progeny could contain modified genes. This is the basis for concern over the movement of 
herbicide resistance genes from GM canola to wild mustard, a closely related weed species 
(Black, 2004). The second component of the genetic model focuses on the potential for genes 
to escape the GMO through non-sexual means, such as horizontal gene transfer (HGT) 
(Syvanen, 1994). Research with transgenic plants suggests that HGT happens rarely (Droge, 
Puhler, & Selbitschka, 1998), but the risk may still be salient for consumers (Wu, 2004). The 
central question with regard to this model is thus the length of the vector from the GMO into 
the world of closely and distantly related species, with one vector for each of the two 
components. 
 
Figure 2: Genetic model of GMO impacts 
 
Distantly related species 
Sexual 
Asexual 
GMO 
Closely related 
species 
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The third mental model that also arises in discussions of consumer reactions to GMOs, 
captured in Figure 3, is based on how food is produced (Marvier, 2007; Mewett et al., 2007). 
The GMO is the source of the modified genetic material, which the consumer experiences not 
through the organism (as in the environmental model) or its genes (as in the genetic model) 
but through food products. One important dimension is the extent to which the product is 
processed.  Each extra ingredient adds a possibility of including GM ingredients, and each 
industrial food ingredient (e.g., high fructose corn syrup) adds to the probability of food 
ingredients being derived from GM crops, such as soyabeans and maize. Increased processing 
also increases the possibility of adventitious presence, either of ingredients that were not 
supposed to be GM, or of unintended ingredients (as when packaging indicates that the 
product ‘may contain nuts’). A second dimension concerns the source of the food. Some 
sources may be assumed to be GM-free. For example, crops grown in New Zealand are 
supposed to be free of GMOs (Scandurra, 2007). Other sources are relatively certain to 
contain GMOs, such as soybeans grown in the US (James, 2005). Both dimensions have 
gradients from ‘certain to be non-GM’ to ‘definitely contains GMOs’. The gradients are 
indicated in Figure 3 by shading. The lighter the shading, the more likely a food product is to 
contain GM material. 
 
 
Figure 3: Production model of GM status of food 
 
 GM Status of Source 
non-GM GM  
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One further aspect of consumer thought that these models do not explicitly capture is the 
difference between what should happen and what does happen. The difference between the 
two has shown up in the StarLink incident (Lin, Price, & Allen, 2001-2002), the 
contamination of US rice with an unapproved variety, and problems with ProdiGene’s 
biopharming activities (Ramessar et al., 2008). Einsiedel & Medlock (2005) found that 
people made judgements about the safety of biopharming based in part on the idea that 
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regulators did not have the skill or resources to enforce full compliance with regulations. One 
view is, as Marvier  (2007) notes after reviewing several examples of adventitious presence 
of GM crops, ‘Human error occurs and, frankly, is unavoidable’ (p. 61). These concerns 
around non-compliance and error create uncertainty in all these models, and individuals’ 
assessments of that uncertainty will affect their overall judgement of biopharming. 
 
It should be emphasised that the three figures above are pictorial representations of mental 
constructs that underlie discussion of the impacts of GMOs on food and agriculture. They do 
not purport to be complete or mutually exclusive. Genetic and biological impacts of GM 
crops are occurring simultaneously on farms, and the crops become ingredients that are 
combined into food products for retail sale. The figures also do not purport to be exact. The 
sizes and lengths of different components may not exactly conform to the known or perceived 
impacts of GMOs. However, these mental models – ecological, genetic, and production – are 
a useful starting point for a discussion of potential impacts of biopharming on consumer 
perceptions of New Zealand agriculture. 
 
If New Zealand permits biopharming, the consumer impact will depend on the mental models 
that consumers use to evaluate this development and how the activity responds to any 
concerns raised. The ecological model will consider the potential impacts on the farm and 
surrounding ecosystems. The essential question is the size of the dotted oval in Figure 1 and 
the ability of the biopharming industry to keep the oval as small as possible. That is, 
measures will be taken to limit the spread of pollen, keep waste products from moving into 
the wider environment, and demonstrate the safety of the crop for organisms such as 
butterflies. These measures may convince consumers that the impact oval is really quite 
small. On the other, some consumers may perceive that the behaviour of an organism – GM 
or not – in an environment is resistant to control, so that the impact oval remains relatively 
constant despite the industry’s efforts. For these consumers, organisms will always escape 
control, in a sort of ecological second law of thermodynamics (systems tend towards 
entropy). 
 
The genetic model provides a different view of the possible spread of biopharm GMOs, this 
time at the level of the genetic material. Consumers may perceive that the main impact would 
be through the cross-breeding of biopharm crops with other species, either domestic or wild. 
In this case, the concern can be allayed by using biopharm crops that do not have sexually 
compatible relatives in the surrounding environment (Fontes, 2007; Marvier, 2007; Mewett et 
al., 2007). Perceptions regarding the other method of spread of biopharm genetic material, 
asexual transfer, may be more difficult to address. If consumers perceive that genetic material 
can move about in the environment in largely unregulated ways, then any attempt to predict 
or control these movements would be at best difficult and at worst wishful thinking. This 
impact is again a sort of entropy, with genetic material always seeking to escape its 
containment within a specific organism. 
 
The production model is based around uncertainty and probability. Consumers using this sort 
of mental model are not evaluating a specific crop or its ecosystem, but rather are considering 
the possibility that GM ingredients could end up in food and whether they would be able to 
tell. There are two consequences of this model. First, the intentions of biopharm producers do 
not enter into the assessment. Whether or not the GM material ends up in food is a function 
of the food system, not the behaviours or intentions of individual producers. The only way to 
avoid GM food is to buy whole foods from perceived GM-free sources (such as organic 
farms or countries that do not grow GM crops). Secondly, New Zealand’s status along the 
horizontal axis may be broad-brush and resistant to change. This stickiness is evident in the 
country’s ‘clean and green’ image. Studies have suggested that New Zealand’s agriculture is 
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not as environmentally friendly as its image suggests, but yet the image persists 
(Parliamentary Commission for the Environment, 2004). This is akin to the experimentally 
observed failure in mental processing, failure to update base probabilities. That is, consumers 
expect New Zealand to be clean and green, and that rule of thumb is stronger than any new 
information. The rule-of-thumb decisions can cut both ways, however. If a biopharm crop is 
grown in New Zealand, the country as a whole could become ‘one of the GM countries’. Its 
position along the horizontal axis of Figure 3 would move farther to the right, with a 
corresponding increase in a perception that New Zealand food is GM food. 
 
The overall impact of a release of a biopharm crop in New Zealand will depend on the mental 
models that consumers are using to evaluate the release. Both the environmental and genetic 
models include the possibilities that producers can keep GM material out of the food supply. 
They also both include the possibility that GM material will escape confinement or control 
and become part of the wider environment. Given this aspect of both models, it is interesting 
that the issue of biopharming is actively being framed as one of a technical ‘containment or 
confinement problem’ (Spok, 2006, p. 76). That is, the activities of the regulators and 
industry experts may be in conflict with the mental models that the public are using to make 
sense of biopharming. Finally, the production model suggests that the overall image of New 
Zealand is important, but in addition that perceptions that food products are GM can be 
overcome by focusing on whole foods whose GM status consumers can more clearly 
evaluate.  
 
As a result of this assessment of potential consumer reactions to the introduction of 
biopharming, the present research considered the possibility that consumers could have either 
narrow or wide views of the potential impacts. In the narrow view, biopharming is well 
monitored and controlled, and biopharm crops are effectively segregated from food. In the 
wide view, biopharm crops are potentially in the food system, so consumers are less willing 
to buy New Zealand products. The modelling reported in the next chapter thus included 
scenarios in which consumers are not concerned as well as scenarios with different levels of 
consumer concern. 
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Chapter 3 
Method for Analysing Impacts 
 
3.1 Introduction 
A model of international trade in agricultural commodities was used to analyse the impact of 
changes in agricultural markets due to the introduction of biopharming into New Zealand. 
Economic modelling allows researchers to do three things. First, it provides estimates of the 
economic effects of specific changes to international agricultural market, which measures the 
absolute impacts of policies and technological developments. Secondly, researchers can 
develop many different scenarios and model them. The results provide information about the 
relative sizes of economic impacts of these different versions of the future. Thirdly, 
modelling enables researchers to investigate the relative impacts of different elements of a 
system to identify those elements that are important. 
 
As discussed above, biopharming in New Zealand could have a number of impacts on the 
agricultural sector, and these impacts could be larger or smaller. Considerable uncertainty 
surrounds the eventual production, consumption, and regulatory environment of biopharming. 
Therefore, a number of scenarios were developed to represent several possible futures for 
New Zealand, and these scenarios were then modelled. 
 
This chapter discusses the method for analysing the potential impacts of biopharming in two 
parts. The first part presents the model used for the analysis, including the equation structure 
and the model parameters. The second part describes the scenarios that were developed and 
the specific techniques for modelling them. The results of the analysis are left to the next 
chapter. 
 
3.2 The model structure 
The model is built on the platform of the Lincoln Trade and Environment Model (LTEM) 
(Cagatay & Saunders, 2003; Saunders, Moxey, & Roningen, 2001). It is a non-spatial, partial 
equilibrium model of international agricultural trade developed originally from SWOPSIM 
(Roningen, 1986; Roningen, Dixit, Sullivan, & Hart, 1991), later VORSIM (Roningen, 
2007), and its model structure. It is a synthetic model, based on parameters taken from the 
literature. The model used for the present research comprises 17 specific countries or regions 
plus the Rest of the World (ROW), and contains 22 commodities, including three for the 
oilseed complex and five for the dairy industry. These commodities are considered 
homogenous with respect to country of origin. 
 
The LTEM can explicitly consider various domestic and border policies, including 
production quotas, set-aside policies, input and/or output related producer subsidies/taxes, 
consumer subsides/taxes, minimum prices, import tariffs and quotas, and export subsidies and 
taxes. The parameters associated with these policies can be modified to simulate policy 
changes in order to estimate their economic impacts.  
 
The dynamic framework of the LTEM allows the paths of endogenous variables to be 
assessed through the modelled time period, and a comparative statics analysis can be 
conducted by comparing different years or the final results of different policies. The model 
seeks a price equilibrium of a series of production, consumption, and trade equations for each 
year, solving each year in succession until the final period. The structure of the model is 
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based on a set of supply and demand equations and one economic identity for each 
commodity in each country. These are presented below with an explanation following each 
equation. 
 
ppij = f(WDppi, Zsij, forex) (1) 
 
The producer price (pp) for a commodity (i) in a specific country (j) is a function of the world 
producer price for the commodity (WDppi); the country’s policies, especially producer 
policies, affecting the commodity (Zs); and the exchange rate (forex). 
 
pcij = g(WDppi, Zdij, forex) (2) 
 
The consumer price (pc) for a commodity is also related to the world producer price for the 
commodity, but is additionally affected by the country’s policies affecting demand (Zd) and 
the exchange rate (forex). 
 
qpij = h(fpij, Zj, ppij, ppkj, qpij, t-1) (3) 
 
The level of production of a commodity is influenced by the country’s policies (Zj), the 
producer price for the commodity, the producer price for other complementary and substitute 
commodities (ppkj, k ≠ i), and a one-year production lag term (qpij, t-1). In addition, the 
production equation includes a parameter, fpij, that can be used to shift productivity from its 
base levels. This parameter represents changes in production that are exogenous to the model 
and affect the relationship between prices and quantities, such as introduction of a new 
cultivar or a new production technology. Because the production equation uses a constant 
elasticity of substitution functional form, the generated shift is pivotal. 
 
qcij = mfood(fcij, Zj, pcij, pckj, GDPj, popj) (4) 
 
The disappearance of a commodity is divided into food, feed, and processing components, 
with the residual disappearance included in the trade identity (see below). Food demand (qc) 
is modelled as a function of policy variables (Z), the consumption price of the commodity, 
the consumption price of other commodities (pckj, k ≠ i), an index of gross domestic product 
(GDP), and the country’s population (pop). This equation also includes a shift variable, fcij, 
which allows exogenous changes to consumption to be modelled. 
 
qfij = mfeed(fcij, Zj, pcij, pckj, qpkj) (5) 
 
Some commodities have a feed component of their disappearance. The feed demand of a 
commodity (qf) is based on policy variables, the commodity’s own price, and the prices of 
other commodities (pckj, k ≠ i). The feed demand is also affected by the production of 
livestock commodities, such as beef and dairy products, and these enter directly into the 
equation. Finally, the feed equation contains a shift variable for exogenous changes to feed 
consumption. 
 
qrij = mproc(ppij, ppkj, qrij, t-1) (6) 
 
For the oilseed complex, the model contains equations for processing demand. This demand 
is a function of the commodity’s own price, the prices of co-produced products (ppkj, k ≠ i), 
and the processing in the prior period (qrij, t-1). 
 
qeij = n(qpij, qcij, pcij, qeij, t-1) (7) 
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Commodities have a stock equation to account for changes in inventory. The ending stock of 
a commodity (qe) is based on the quantity produced, the quantity consumed, the consumer 
price of the commodity, and a lag variable for the prior year’s ending stock. 
 
qtij = qpij – qcij – qfij – qrij – Δqeij (8) 
 
The final equation in each country is an identity that sets the amount of trade (qt) equal to the 
quantity produced less consumption, feed uses, processing uses, and the change in ending 
stocks. This quantity traded, positive in the case of exporting countries and negative in the 
case of importers, then becomes part of the world trade equation. 
 
The world trade equation sums the quantity traded over all countries and region for each 
commodity. The model is solved by finding the world producer price (WDppi, see above) that 
allows the net world trade to sum to zero, or for total imports to equal total exports. The 
model is calibrated for the base year of 2004, and then solved for each successive year. In the 
biopharming research, the model projects impacts out to 2020. 
 
3.3 Scenarios modelled 
The trade model was used to assess the potential impacts of biopharming given certain 
scenarios regarding production and consumption. The first consideration for the modelling 
was whether to make the pharmaceutical production endogenous to the model. Given the 
early stage of the technology and the large uncertainties regarding choice of bioreactors, 
markets, regulations, and other aspects, pharmaceutical production was not included within 
the model. Instead, the impacts of biopharming on the agricultural sector were estimated. 
These represent impacts in addition to the direct economic impacts of the pharmaceutical 
derived from a biopharming method of production. To illustrate, a therapeutic protein may be 
able to capture revenue of NZ$100 million. To do this might entail reduction of agricultural 
production elsewhere or the imposition of greater costs on other producers (for example, 
segregation costs) of NZ$10 million. The net change in revenue for New Zealand would be 
NZ$90 million. The modelling described here would be the source of the NZ$10 million 
number, while the NZ$100 million would be estimated separately from the model. 
 
Extent of biopharming impacts 
 
A key input into the LTEM is the level of uptake of different farming practices. For every 
country and every commodity, it is possible to specify how much production is conventional 
and how much uses some other technology. For the present modelling, this variable was used 
to set a base assumption about the extent to which a country’s agriculture was linked to or 
affected by biopharming. Countries were grouped into three different categories, as shown in 
Table 1. Several countries were modelled as avoiding biopharming, such as by not licensing 
biopharming production within their borders. These countries/regions were the EU, Japan, 
and Norway. Several other countries were modelled as having high uptake of biopharming. 
These countries would have commercial biopharm crops and would be understood by the 
international market to allow commercial biopharming. These countries were Canada, 
Switzerland, and United States. For purposes of this research, it was also assumed that New 
Zealand had wide adoption of biopharming. The other countries in the LTEM were modelled 
as having intermediate levels of biopharming adoption. They would neither ban it nor have 
widespread adoption. 
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Table 1: Adoption levels of biopharming for LTEM 
countries/regions 
High adoption 
(90 per cent) 
Intermediate adoption 
(50 per cent) 
Low adoption 
(1 per cent) 
Canada Argentina European Union (25) 
New Zealand Australia Japan 
Switzerland Brazil Norway 
USA China  
 India  
 South Korea  
 Mexico  
 Russian Federation  
 South Africa  
 Turkey  
 Rest of the World  
 
 
Production impacts 
 
One way that biopharming could affect agriculture is by its impacts on the supply side or 
production. Supply impacts are those changes that affect how a product is produced or the 
efficiency of production. These impacts tend to be technology changes or policy changes that 
affect the cost of production. One possibility is that biopharming will not have any 
appreciable impact on the wider agricultural sector. That is, there may be a few niche 
producers with stringent segregation protocols and high costs, but the only wider impact is a 
slight reduction in overall production. A second possibility is that the introduction of 
biopharming creates costs for all producers, with increasing regulation and reporting in order 
to maintain segregation of food and pharmaceutical crops. In that case, biopharming may 
cause the cost of production to increase generally. This can be modelled as a shift of the 
supply curve to the left as the per-unit cost of supplying products increases.  
 
It is important to emphasise that if biopharming leads to farmers growing crops with higher 
value in the market (absent a technological change in production), this is a demand impact, 
not a supply impact. That is, farmers may receive a higher price for their products, but the 
higher price is a result of higher demand for the biopharming crops. A price change is not 
reflected in a shift of the supply curve. 
 
The prior report on biopharming (Kaye-Blake et al., 2007) examined specific products and 
applied an economic model to assess their costs and benefits. One such product was human 
lactoferrin produced in cows’ milk. Human lactoferrin has been the target of much 
biopharming research and commercialisation effort, and biopharming research in New 
Zealand has specifically examined producing such compounds in cows’ milk. To create a 
realistic scenario and to link this report to the prior one, the modelling was restricted to 
include just the dairy sector. Other commodities in the model were not modelled as having 
production (or consumption) impacts. 
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Taking the possibilities described above into account, this research modelled three supply 
shifts. The first shift was that biopharming had no impact on the rest of the dairy sector or the 
wider agricultural sector. In this case, the supply shift variable fp (eq. 3) remained at 1.00, the 
base value, for New Zealand dairy production. Alternatively, the introduction of biopharming 
could lead to greater costs across the dairy industry. Scenarios were modelled that included a 
five per cent increase in costs and a ten per cent increase in costs. For these scenarios, fp was 
set to 0.95 and 0.90, respectively, for dairying in New Zealand. 
 
Consumption impacts 
 
The demand side of the LTEM could react positively or negatively to the introduction of 
biopharming. If farmers began producing pharmaceutical compounds in milk, that milk 
would be a high-value product. The size of the positive impact on the dairy sector would 
depend on how much of the dairy sector was given over to biopharming and the size of the 
premium that farmers were paid for producing biopharm milk. These topics were explored in 
Kaye-Blake, et al. (2007); the overall finding was that the increase in farm revenues (as 
opposed to revenue to biopharmaceutical companies) is uncertain but likely to be small. 
However, there is also the potential for a negative impact. The three models of consumer 
reactions described above – ecological, genetic, and production – describe different ways that 
consumer might understand the interaction of biopharming with food farming. If consumers 
perceive that biopharming is contained, then there is not likely to be a negative consumption 
effect from embarking on biopharming. On the other hand, these models describe different 
ways that biopharming might be perceived as ‘contaminating’ the food supply. If consumers 
become concerned about the potential for contamination, then negative consumption effects 
could result. The net consumption impact in the LTEM is the sum of the positive and 
negative effects. 
 
To model the potential impacts, five different levels for the consumption impact were 
considered. One possibility is that the positive and negative impacts are so small as to be 
imperceptible at the level of whole dairy industry. For example, biopharm milk could be a 
niche product with low premiums, and consumers may not know or care that it is happening. 
In this case, the demand for milk from areas with biopharming would not be affected, and the 
shift variable, fc (eq. 4) would remain at 1.00, the base level. Another possibility is that the 
premium paid to farmers for biopharm milk is sufficiently large and/or widespread to boost 
the demand for the whole industry. In that case, fc would shift upwards to reflect the greater 
demand for dairy products. For the present research, fc was changed to 1.10, a 10 per cent 
increase in demand. This could be the result, for example, of a 100 per cent premium paid to 
10 per cent of the industry. 
 
The net impact on the industry could also be negative. Consumers’ concern about milk 
produced in areas where biopharming is permitted could be sufficiently large that demand is 
reduced, and this reduction is large enough to overwhelm any premium that farmers receive 
from higher-value biopharm milk. Three different levels of demand reduction were modelled. 
One level was a relatively modest 10 per cent reduction in demand, modelled by changing fc 
to 0.90. A second level was a larger reduction of 20 per cent, with an fc of 0.80. Finally, a 
very large shift of 50 per cent was also modelled, for which fc was set at 0.50.  
 
The way that the LTEM is constructed effected how these consumption shifts were modelled. 
The increases and decreases in demand affected only that consumption linked to bipharming 
areas. Consumption linked to areas where biopharming does not occur – the conventional 
production – did not have direct impacts, although they did have indirect impacts through 
cross-elasticities with other markets. 
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Modelled scenarios 
 
Each scenario entailed setting the above production and consumption impacts, given the 
assumptions about the extent of biopharming impacts, and then simulating international trade 
in agricultural commodities to the year 2020. In the base scenario, biopharming had no 
impact on production or consumption, so the shift variables were set to 1.00. In all other 
scenarios, fp, fc, or both were changed to simulate the different changes in agricultural 
markets. The scenarios considered in this modelling were presented in Table 2. Results are 
presented and discussed in the next chapter. 
 
 
Table 2: Biopharming scenarios modelling 
 Consumption impacts 
Production 
impacts 
10% 
increase No change 
10% 
reduction 
20% 
reduction 
50% 
reduction 
No change B01 Base B06 B09 B13 
5% cost 
increase B02 B04 B07 B10 B14 
10% cost 
increase B03 B05 B08 B11 B15 
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Chapter 4 
Results and Discussion 
 
 
4.1 Modelling results 
Each model scenario provided a different estimate of future revenues to the agricultural 
sector given the use of biopharming in New Zealand (and elsewhere in the world) and 
specific assumptions about the costs that biopharming creates for the rest of the agricultural 
sector and consumers’ reactions to the new technology. Total revenues to agriculture in New 
Zealand were calculated for each scenario and compared with results from the base scenario. 
The net impact could then be expressed as a change from the base. The results are presented 
in Table 3. 
 
 
Table 3: Scenario results: change in New Zealand producer returns (%) 
 Consumption impacts 
Production 
impacts 
10% 
increase No change 
10% 
reduction 
20% 
reduction 
50% 
reduction 
No change 2.9 -- -3.0 -6.1 -16.8 
5% cost 
increase 2.1 -0.7 -3.6 -6.7 -17.2 
10% cost 
increase 1.4 -1.4 -4.3 -7.3 -17.6 
 
 
The first column of result in Table 3 concerns those scenarios in which agricultural revenues 
are higher as a result of premiums paid for producing biopharm crops. The first of these 
scenarios examined only a demand increase: biopharm dairy products attracted premium 
prices for farmers, and no extra costs were imposed on the rest of the sector. The premium 
prices increased total New Zealand producer returns by 2.9 per cent. Thus, if the country 
adopted biopharming and the dairy sector attracted the premium modelled – for example, a 
100 per cent premium on 10 per cent of milk – then agricultural revenues increased by around 
three per cent. This increase was reduced as biopharming led to greater costs on the dairy 
sector. Segregation costs that created a five per cent cost shift reduced the gains to 2.1 per 
cent; if the costs doubled, then the gains to the sector were 1.4 per cent. 
 
The second column of Table 3 shows the results given no consumption impacts. In these 
scenarios, biopharming did not change aggregate demand for dairy products. The only 
impacts were on the costs of production. This column contains the base scenario – no 
production or consumption impacts. It also contains two further scenarios, one with a five per 
cent increase in costs and the second with a 10 per cent increase. The first scenario reduced 
total producer returns in New Zealand by 0.7 per cent, while the second reduced returns by 
1.4 per cent. The pivotal shift backwards of the supply curve, representing an increase in 
costs, moved the equilibrium position of international markets along the original demand 
curve, leading to reduced production and a higher price. The net effect was a small reduction 
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in farm revenues. The demand effect in this case was not due to any consumer reactions to 
biopharming. These solutions had no consumption shifts, so the demand effect was simply a 
reaction to the reduced supply due to higher production costs. 
 
The next three columns in Table 3 present the model results given negative consumer 
reactions to the introduction of biopharming.  These were net changes in demand, so they 
include both premiums paid for higher-value dairy products as well as consumer reluctance to 
consume dairy products from biopharming areas. These three columns present the modelling 
results given a net 10 per cent, 20 per cent, or 50 per cent reduction in consumer demand for 
dairy products from countries or areas that allow biopharming. The consumption shifts were 
considered against the three production impacts. When biopharming had no general impact 
on the cost of producing dairy products, then the net reduction in producer returns was 3.0 per 
cent with a 10 per cent reduction in demand, increasing to a 16.8 reduction with a 50 per cent 
reduction in demand.  As production costs increased, producer returns fell further. The largest 
impact was seen with a 10 per cent increase in costs and 50 per cent reduction in demand, 
which together produced a fall in producer returns of 17.6 per cent.  
 
4.2 Discussion 
The results from a partial equilibrium trade model are best understood not as point estimates 
of what will happen in the future, but as an indication of tendencies. The several scenarios 
should be examined together to understand the overall picture of potential impacts. 
 
One general result from these scenarios was that the impacts of cost changes were relatively 
small compared to those scenarios with no costs impacts. In all scenarios, the impact of 
increasing the costs of production to accommodate biopharming was less than two per cent of 
total producer returns to the agricultural sector. This result suggests that if successful 
development of bipharming in dairy cows required segregation or identify preservation 
techniques across the whole dairy sector, the cost to the whole sector would not necessarily 
be high. The findings here are similar to those in prior research regarding productivity 
increases, although in the opposite direction. Prior research has found that increases in 
productivity do not necessarily lead to large gains to New Zealand’s agriculture, and may 
even reduce producer revenues (Kaye-Blake, Saunders, Emanuelsson, Dalziel, & Wreford, 
2005; Saunders & Cagatay, 2003). 
 
A second general result is that the demand impacts from the introduction of biopharming are 
larger than the production impacts and will probably determine to size and direction of the 
net result. If total demand for New Zealand dairy products increases as a result of the 
production of high-value biopharm products, then the net result is likely to be positive even 
with increased costs. On the other hand, negative consumer reactions overseas to the 
introduction of biopharming in New Zealand can be expected to reduce producer returns and 
shrink the agricultural sector. Again, the importance of consumers’ reactions is similar to 
prior findings. 
 
The mental models discussed in Chapter 2 have a bearing on these results. In the modelling 
presented here, the assumption was that production and consumption impacts were confined 
to the dairy sector. The biopharm product was assumed to be something like lactoferrin 
produced in dairy cows (Kaye-Blake et al., 2007). Biopharming could create additional costs 
for segregation in the dairy sector, and consumers might have positive or negative reactions 
to dairy products from New Zealand. These impacts are relatively restricted, given to models 
of potential reactions presented above. From an ecological standpoint, this approach confines 
the impacts of biopharming to the product itself without considering the impact on the farm 
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or wider ecology. One consideration, for example, would be the effluent, which is known to 
interact with the ecology of the pasture as well as surface water and groundwater. From a 
genetic standpoint, the impacts described here are probably complete because cows would 
not be out-crossing with wild bovine species, but they do not preclude greater concern for 
asexual genetic impacts. Finally, from a production standpoint, consumer could perceive 
greater impacts than assumed. Commencing biopharming activities in New Zealand could 
lead to a generalised impression that products from the country are tainted or not to be 
trusted. In addition, the fact that dairy products are themselves processed and are also 
included in many processed foods could lead consumers to a belief that biopharm products 
were leaking into the food system via processing. The three mental models suggest ways in 
which the assumptions underlying the trade model scenarios regarding potential impacts on 
the agricultural sector might be too narrow. Consumer concerns could extend to the wider 
agri-food system or the wider environment. In that case, the impacts could be expected to 
increase. 
 
The modelling results also provide information relevant to a cost-benefit analysis of 
biopharming. A biopharming industry could start producing commercial quantities of 
biologic compounds in New Zealand, which would represent an increase in economic activity 
in the country and thus a benefit to the economy. If the net impact on the agricultural sector 
were also positive (as a result of higher payments to farmers), then the overall impact would 
definitely be positive. If, on the other hand, the net impact on the agricultural sector were 
negative, the losses to agriculture would represent a cost to introducing biopharming. The 
overall economic impact would depend on the sum of the costs and benefits. Using the trade 
modelling results, it is possible to calculate roughly the overall impact on the agricultural 
sector. According to the Ministry of Agriculture and Forestry, gross agricultural revenue was 
$19,047 million in 2007 (Ministry of Agriculture and Forestry, 2007, Table 2.4). The result 
for scenario B04, with no consumption impact and a five per cent increase in costs for the 
dairy sector, was -0.7 per cent, or $133 million in current dollars at today’s level of 
production. This figure suggests that biopharming would need to generate sufficient revenue 
to offset agriculture’s lost revenue of $133 million annually (in 2007 dollars) to leave the 
country’s economy unaffected as a whole. The greatest impact modelled, scenario B15, leads 
to a calculation of $3,352 million in lost revenue. Thus, the potential impacts cover a range of 
values. 
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Chapter 5 
Conclusion 
 
 
This report has examined the potential impacts of the introduction of biopharming on the 
New Zealand economy. It summarised a prior report by the authors on this topic (Kaye-Blake 
et al., 2007), updated it with more recent literature, and systematised the literature by 
organising consumers’ reactions into three mental models. The report then quantified various 
assumptions regarding technology uptake, production, and consumption, and modelled the 
net effects of those assumptions on New Zealand agriculture using a model of international 
trade, the LTEM. Finally, it used the model results to calculate possible economic impacts of 
biopharming on the agricultural sector. 
 
The general message of the earlier report remains despite the further research that has been 
conducted. The economic case for biopharming is still uncertain as too many dimensions 
regarding production of the crop and the biologic are not known. One researcher (Spok, 
2006) has suggested that the emphasis on cost reduction had lessened, with current thinking 
on biopharming shifting to the different types of production and compounds that could result. 
Nevertheless, the literature still refers to the expected cost-efficiencies of production. In 
addition, the benefits of new compounds or new methods would need to be quantified in 
order to develop a full analysis of the economic impacts of biopharming; this quantification is 
not yet available. 
 
In the face of this uncertainty, a modelling exercise can consider a range of impacts and 
quantify their possible net effects. The LTEM, a model of international trade in agricultural 
commodities, was used for this purpose. It estimated the potential impact on agriculture of 
biopharming; the impacts on the pharmaceutical industry were left for a future analysis. It 
was assumed, firstly, that New Zealand was one of several countries that decided to pursue 
biopharming, but that other countries did not. Production of a biopharm product using dairy 
cows was modelled as having either no effect on the general costs of dairy production or 
some small impact on those costs. The introduction of biopharming was also assumed to 
influence demand for dairy products; the net demand impact was modelled as positive, 
neutral, or negative. 
 
The modelling results indicated that biopharming could affect agriculture either positively or 
negatively. The main factor in determining the size and direction of the effect was the change 
in demand. If demand for dairy products increased (because the products were of higher 
value and farmers were paid a premium), then the net impact was likely to be positive. If 
consumers became wary of New Zealand dairy products, then the result was likely to be 
negative. Of less importance was the imposition of greater costs on the sector for segregation 
of food and biopharm milk. At the cost levels modelled, the impact was a reduction in 
agricultural revenues of less than two per cent. 
 
The results from the trade modelling provide a baseline for a cost-benefit analysis of the 
introduction of biopharming. If biopharming results in higher agricultural revenues, then the 
total economic impact is likely to be positive. If, on the other hand, biopharming imposes 
costs on the agricultural sector or leads to negative consumer reactions through any of the 
mental constructs described above, then it would need to offset those costs in order to have a 
positive economic contribution overall. The size of the offset depends on the size of the 
production and consumption impacts. The modelling conducted for this research resulted in 
lost revenues to the agricultural sector of $133 to $3,352 million annually in current dollars. 
 24
Figures from Kaye-Blake, et al. (2007) provide a useful comparison: the annual market for a 
single compound that could be produced with this technology, lactoferrin, was about US$27 
million in 2004, while total worldwide sales for ‘healthy’ and functional foods are around 
US$25,000 million to US$36,000 million per year. These figures, however, give only an 
indication. It is still too early to conduct a full, robust cost-benefit analysis or to predict 
whether the net effect of biopharming on the New Zealand economy would be positive or 
negative. 
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